Top Stocks to Buy: Expert Recommendations for the Week Starting November 10, 2025
The Times of India Business Desk – November 10, 2025, 08:56 IST
As the financial markets continue to evolve rapidly, investors eagerly look for actionable guidance to make informed decisions. For the week beginning November 10, 2025, Motilal Oswal Financial Services Ltd has identified two promising stocks that appear well-positioned for growth and value creation: L&T Finance and Rubicon Research. Here is a detailed overview of these top stock picks and the rationale behind their recommendation.
L&T Finance: Driving Growth Through Digital Transformation
- Current Market Price (CMP): Rs 304
- Target Price: Rs 330
- Upside Potential: 10%
L&T Finance is undergoing a dynamic transformation to emerge as a “risk-first, tech-first, multi-product retail financier.” This strategic pivot is powered by advanced digital platforms such as Cyclops and Nostradamus, which drive risk-calibrated growth and operational efficiency.
With AI-driven underwriting, automated portfolio management, and strategic partnerships with top digital ecosystems including PhonePe and Amazon, L&T Finance is significantly enhancing its scalability, customer base, and asset quality. The firm’s expansion into high-yield segments such as gold loans, combined with disciplined growth across retail, SME, and rural finance segments, is helping to diversify and stabilize its earnings profile.
Improvements in return ratios, continuous expansion of digital capabilities, and a focus on sustainable retail-led growth make L&T Finance a well-placed contender to deliver consistent profitability and long-term value for shareholders.
Rubicon Research: Strengthening Its Footprint in Regulated Pharmaceutical Markets
- Current Market Price (CMP): Rs 626
- Target Price: Rs 740
- Upside Potential: 18%
Rubicon Research is steadily reinforcing its reputation as a research-driven pharmaceutical player, with a strategic focus on regulated markets, particularly the United States. The company’s core competitive advantages include strong research and development capabilities, efficient manufacturing infrastructure, and a robust track record of regulatory compliance.
Rubicon has reported healthy growth in revenue and profitability, bolstered by successful product launches in generics and nasal spray segments. Its focus on prescription-driven central nervous system (CNS) therapies showcases its commitment to innovation and addressing unmet medical needs.
Operational excellence is evident from the company’s strong commercialization achievements and disciplined product execution. Continued emphasis on innovation, regulatory adherence, and cost efficiency positions Rubicon Research for sustainable long-term growth.
Summary Table
| Company | Current Market Price (Rs) | Target Price (Rs) | Upside (%) |
|---|---|---|---|
| L&T Finance | 304 | 330 | 10 |
| Rubicon Research | 626 | 740 | 18 |
Expert Disclaimer
It is important for investors to consider that the stock recommendations and views expressed are those of the experts at Motilal Oswal Financial Services Ltd. These opinions do not necessarily represent the views of The Times of India. Investors should perform their own due diligence or consult financial advisors before making investment decisions.
About the TOI Business Desk
The Times of India Business Desk is a dedicated team of journalists committed to delivering the latest and most reliable business news worldwide. The desk covers diverse industries, market trends, and economic analyses to keep readers well-informed about global commerce developments.
Stay tuned to The Times of India for more stock market insights, financial news, and expert market analysis to help you navigate the complexities of investing successfully.
Related Articles & Features
- Meesho IPO updates
- New Labour Codes and their impact on businesses
- Daily gold, silver, and platinum rates
- Cybersecurity regulations affecting markets
For real-time updates and comprehensive market coverage, visit timesofindia.com/business.
This article is intended solely for informational purposes and should not be considered as financial advice.